Correction: The effect of dapagliflozin on cardiorespiratory fitness in patients with coronary heart disease and type 2 diabetes mellitus following PCI: a single-center prospective randomized controlled study - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Impact of Dapagliflozin on Cardiorespiratory Fitness in Individuals with Coronary Heart Disease and Type 2 Diabetes Mellitus Post-PCI: A Prospective Randomized Controlled Trial at a Single Center

  • By

  • Jiali Yang

  • Xinru Li

  • Liangqiu Tang

  • Wenmao Fan

  • Aihua Li

  • Wanming Zhou

  • Jungang Pang

  • Qiuxiao Yuan

  • Ming Zhong

  • Jinhui Hou

  • Lan Wang

  • Wenjiao Liao

  • Xiangyang Liu

  • BMC Cardiovascular

  • June 2, 2026

Share

Original Source(s)

Correction: The effect of dapagliflozin on cardiorespiratory fitness in patients with coronary heart disease and type 2 diabetes mellitus following PCI: a single-center prospective randomized controlled study

  • by Jiali Yang, Xinru Li, Liangqiu Tang, Wenmao Fan, Aihua Li, Wanming Zhou, Jungang Pang, Qiuxiao Yuan, Ming Zhong, Jinhui Hou, Lan Wang, Wenjiao Liao, Xiangyang Liu, BMC Cardiovascular

  • June 2, 2026

Related Content

PAHR: Prognostic Marker in Severe Aortic Stenosis?

Researchers evaluated whether a composite measure of heart rate and pressure could capture overall hemodynamic burden.

Association of DAPT duration with bleeding and ischemic outcomes after percutaneous coronary intervention with drug-coated balloons: a meta-analysis

Predictors of a prolonged puncture-wire time in patients with ST-Elevation Myocardial Infarction (STEMI)